$21.49▲ 0.61 (2.92%)
Real-time prices · US MarketsHealthy balance sheet and financial position.
currently unprofitable (-32% margin).
Quality
1.3
Health
6.9
Growth
3.3
Valuation
6.7
Sentiment
4.7
Analyst Target
$21.78
▲ +1.4% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
7.2×
next 12 months est.
Market Cap
$2.3B
market capitalization
Div Yield
—
dividend yield
Profit Margin
-32.5%
net profit margin
Gross Margin
-7.4%
revenue minus COGS
ROE
-53.5%
return on equity
Beta
0.28
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$10 — $65
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is SRPT a good stock to buy right now?
Sarepta Therapeutics, Inc.'s Q·Score is 4.4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: currently unprofitable (-32% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for SRPT?
The consensus price target for SRPT is $21.78, based on ratings from 23 Wall Street analysts. This is 1.4% above the current price of $21.49. Price targets are forward-looking estimates and not guarantees of future performance.
Is SRPT overvalued or undervalued?
Sarepta Therapeutics, Inc. (SRPT) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 7.2×.
When does Sarepta Therapeutics, Inc. report its next earnings?
Sarepta Therapeutics, Inc. is scheduled to report earnings in 3 days, on May 6, 2026.
What is Sarepta Therapeutics, Inc.'s profit margin?
Sarepta Therapeutics, Inc. has a net profit margin of -32.5%, indicating the company is currently operating at a net loss. Its gross margin stands at -7.4%, reflecting a more cost-intensive business model.
Is Sarepta Therapeutics, Inc.'s revenue growing?
Sarepta Therapeutics, Inc. is reporting revenue declining 32.7% year-over-year.
How much debt does Sarepta Therapeutics, Inc. have?
Sarepta Therapeutics, Inc. has a debt-to-equity ratio of 0.91×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 2.32×, indicating comfortable short-term liquidity.